EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Neuroblastoma in Infants: Long‐Term Survival From INES Protocols A SIOPEN Study

Julie Savagner iD, Caroline Munzer, Gudrun Schleiermacher iD, Alberto Garaventa iD, Riccardo Haupt iD, Stefania Sorrentino iD, Katia Mazzocco iD, Andrea Di Cataldo iD, Adela Canete iD, Vanessa Segura, Desiree Ramal iD, Kate Wheeler and 10 more

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31982 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Julie Savagner and 21 co-authors. Institution: Pediatric Oncology Department, Hôpital des enfants, Toulouse, France. Major MEDLINE topics: Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols. Cited 5 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Neuroblastoma is the most common extracranial solid tumor in infants, with a possibility of spontaneous regression even in disseminated disease. Despite an overall good prognosis, relapse can worsen the outcome for some patients. A long‐term analysis is crucial to identify subgroups of patients with poorer prognosis, assessing the risks of late relapse, progression or long‐term toxicity associated with multimodal treatment in very young children.

Methods

Estimation of the 10‐year event‐free and overall survivals in 750 infants under 12 months with neuroblastoma, enrolled in the prospective INES protocols between 1999 and 2004. Follow‐up data from INES patients were updated, and survival analyses were performed in order to determine prognostic factors such as age, stage, genomic profile, or MYCN amplification.

Results

Overall, 10‐year overall survival was 91.1% ± 1.0%, and 10‐year event‐free survival was 82.4% ± 1.4%, with significantly better outcomes in infants under 6 months compared with those aged 6–12 months, even considering the MYCN‐amplified tumors only. MYCN amplification was the strongest prognostic factor and was correlated with lower survival in patients with metastatic disease.

Discussion

Survival in patients less than 12 months remains excellent and stable even at long term, as a 10‐year follow‐up did not change the number of events. However, survival in MYCN‐amplified tumors remained poor. Patients with metastatic tumors require accurate risk stratification. For each treatment group, there was no significant difference in long‐term outcomes compared with previous publications from INES. No lethal toxicity affecting long‐term survival occurred.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaAntineoplastic Combined Chemotherapy ProtocolsHumansInfantFemaleMalePrognosisSurvival RateFollow-Up StudiesN-Myc Proto-Oncogene ProteinProspective StudiesInfant, NewbornGene Amplification

Author keywords

INESfollow‐upinfantslong‐termneuroblastomasurvival

Substances

MYCN protein, humanN-Myc Proto-Oncogene Protein

Authors and institutions

  • Pediatric Oncology Department, Hôpital des enfants, Toulouse, France.
  • SIREDO Department for Pediatric Oncology, Institut Curie, Paris, France.
  • RTOP Translational Research in Pediatric Oncology, U830 INSERM, PSL, Institut Curie, Paris, France.
  • Department of Hematology/Oncology, Unit of Pediatric Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Department of Clinical and Experimental Medicine, Unit of Pediatric Hematology-Oncology, University Hospital, Catania, Italy.

ORCID profiles: Julie Savagner, Gudrun Schleiermacher, Alberto Garaventa, Riccardo Haupt, Stefania Sorrentino, Katia Mazzocco, Andrea Di Cataldo, Adela Canete, Desiree Ramal, Ruth Ladenstein, Ana Forjaz de Lacerda, Benedicte Brichard, Maja Beck-Popovic, Dominique Valteau-Couanet, Claudia Pasqualini, Carole Coze, Benoit Dumont, Anne Sophie Defachelles

Cite

APA

Savagner, J., Munzer, C., Schleiermacher, G., Garaventa, A., Haupt, R., Sorrentino, S., Mazzocco, K., Di Cataldo, A., Canete, A., Segura, V., Ramal, D., Wheeler, K., Ladenstein, R., de Lacerda, A. F., Brichard, B., Beck-Popovic, M., Valteau-Couanet, D., Pasqualini, C., Coze, C., …, & Gambart, M. (2025). Neuroblastoma in Infants: Long‐Term Survival From INES Protocols A SIOPEN Study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31982

Vancouver

Savagner J, Munzer C, Schleiermacher G, Garaventa A, Haupt R, Sorrentino S, et al. Neuroblastoma in Infants: Long‐Term Survival From INES Protocols A SIOPEN Study. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31982

BibTeX
@article{Savagner2025,
  author = {Savagner, Julie and Munzer, Caroline and Schleiermacher, Gudrun and Garaventa, Alberto and Haupt, Riccardo and Sorrentino, Stefania and Mazzocco, Katia and Di Cataldo, Andrea and Canete, Adela and Segura, Vanessa and Ramal, Desiree and Wheeler, Kate and Ladenstein, Ruth and de Lacerda, Ana Forjaz and Brichard, Benedicte and Beck-Popovic, Maja and Valteau-Couanet, Dominique and Pasqualini, Claudia and Coze, Carole and Dumont, Benoit and Defachelles, Anne Sophie and Gambart, Marion},
  title = {Neuroblastoma in Infants: Long‐Term Survival From INES Protocols A SIOPEN Study},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31982}
}
Start for free →